207 related articles for article (PubMed ID: 16565242)
1. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression.
Strippoli GF; Craig MC; Schena FP; Craig JC
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S153-5. PubMed ID: 16565242
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive agents for preventing diabetic kidney disease.
Lv J; Perkovic V; Foote CV; Craig ME; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2012 Dec; 12():CD004136. PubMed ID: 23235603
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive agents for preventing diabetic kidney disease.
Strippoli GF; Craig M; Craig JC
Cochrane Database Syst Rev; 2005 Oct; (4):CD004136. PubMed ID: 16235351
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive agents for primary prevention of diabetic nephropathy.
Strippoli GF; Craig M; Schena FP; Craig JC
J Am Soc Nephrol; 2005 Oct; 16(10):3081-91. PubMed ID: 16135776
[TBL] [Abstract][Full Text] [Related]
5. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
Maione A; Navaneethan SD; Graziano G; Mitchell R; Johnson D; Mann JF; Gao P; Craig JC; Tognoni G; Perkovic V; Nicolucci A; De Cosmo S; Sasso A; Lamacchia O; Cignarelli M; Manfreda VM; Gentile G; Strippoli GF
Nephrol Dial Transplant; 2011 Sep; 26(9):2827-47. PubMed ID: 21372254
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
Isaacs AN; Vincent A
J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
[TBL] [Abstract][Full Text] [Related]
8. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Sternlicht H; Bakris GL
Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.
Strippoli GF; Bonifati C; Craig M; Navaneethan SD; Craig JC
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006257. PubMed ID: 17054288
[TBL] [Abstract][Full Text] [Related]
10. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.
Strippoli GF; Craig M; Deeks JJ; Schena FP; Craig JC
BMJ; 2004 Oct; 329(7470):828. PubMed ID: 15459003
[TBL] [Abstract][Full Text] [Related]
11. Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
Krairittichai U; Sarinnapakorn V; Mahannopkul R; Ainwan P
J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S40-7. PubMed ID: 29927180
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
[TBL] [Abstract][Full Text] [Related]
13. The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.
Alsalemi N; Sadowski CA; Elftouh N; Louis M; Kilpatrick K; Houle SKD; Lafrance JP
BMC Nephrol; 2022 Apr; 23(1):161. PubMed ID: 35484505
[TBL] [Abstract][Full Text] [Related]
14. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
15. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin blockade in type 2 diabetic renal disease.
Ruilope LM; Luño J
Kidney Int Suppl; 2002 Dec; (82):S61-3. PubMed ID: 12410857
[TBL] [Abstract][Full Text] [Related]
17. Slowing the progression of renal disease in diabetic patients.
Vivian EM; Goebig ML
Ann Pharmacother; 2001 Apr; 35(4):452-63. PubMed ID: 11302410
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
Huang R; Feng Y; Wang Y; Qin X; Melgiri ND; Sun Y; Li X
PLoS One; 2017; 12(1):e0168582. PubMed ID: 28045910
[TBL] [Abstract][Full Text] [Related]
19. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
20. Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?
Lasaridis AN; Sarafidis PA
Am J Hypertens; 2003 Aug; 16(8):689-97. PubMed ID: 12878377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
